Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flow from operating activities:
Net income	$ 387.6	$ 218.5
Adjustments to reconcile net income to net cash flow from operating activities:
Depreciation and amortization	112.3	143.1
Excess and obsolescence charges related to inventory	17.4	281.5
Share-based compensation	75.6	67.6
Contingent consideration	0.0	(7.1)
Deferred income taxes	(64.5)	1.0
(Gain) loss on strategic investments	79.6	191.1
(Gain) loss on equity method investments	0.0	3.3
Other	31.4	43.3
Changes in operating assets and liabilities, net:
Accounts receivable	77.2	(87.5)
Due from anti-CD20 therapeutic programs	37.6	22.9
Inventory	27.9	(142.6)
Accrued expense and other current liabilities	(295.0)	(461.6)
Income tax assets and liabilities	65.0	101.9
Other changes in operating assets and liabilities, net	(96.8)	(213.6)
Net cash flow provided by (used in) operating activities	455.3	161.8
Cash flows from investing activities:
Purchases of property, plant and equipment	(66.6)	(57.9)
Proceeds from sales and maturities of marketable securities	406.7	543.6
Purchases of marketable securities	(1,321.2)	(1,133.5)
Acquisitions of intangible assets	(5.0)	0.0
Proceeds from sales of strategic investments	33.8	0.0
Other	(0.7)	(0.2)
Net cash flow provided by (used in) investing activities	(953.0)	(648.0)
Cash flows from financing activities:
Payments related to issuance of stock for share-based compensation arrangements, net	(60.1)	(20.8)
Net (distribution) contribution to noncontrolling interest	0.2	0.2
Other	16.5	4.1
Net cash flow provided by (used in) financing activities	(43.4)	(16.5)
Net increase (decrease) in cash and cash equivalents	(541.1)	(502.7)
Effect of exchange rate changes on cash and cash equivalents	20.0	(9.4)
Cash and cash equivalents, beginning of the period	3,419.3	2,261.4
Cash and cash equivalents, end of the period	$ 2,898.2	$ 1,749.3